about
Drug-induced diabetesRandom and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an examplePyrexia, anaemia and acute renal failure secondary to omeprazoleEpisodes of environmental poisoning worldwidePerceptions and Impact of Mandatory eLearning for Foundation Trainee Doctors: A Qualitative EvaluationNominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers)-variants in the spellings of drug names in PubMed: a database review.Laughter and MIRTH (Methodical Investigation of Risibility, Therapeutic and Harmful): narrative synthesis.The lacing defence: double blind study of thresholds for detecting addition of ethanol to drinks.Diuretic therapy for hypertension: a cancer risk?Medication errors that have led to manslaughter chargesDeriving dose limits for warnings in electronic prescribing systems: statistical analysis of prescription data at University Hospital Birmingham, UK.'The strategy of desire' and rational prescribing.The quality of information on monitoring for haematological adverse drug reactions.Calciphylaxis associated with widespread pulmonary calcification.Medicines management: a sour taste.Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine.How NICE may be outflanked.Effects of a computerized feedback intervention on safety performance by junior doctors: results from a randomized mixed method studyOn the alert: future priorities for alerts in clinical decision support for computerized physician order entry identified from a European workshopA systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?Severe relapsing sulphonylurea-induced hypoglycaemia: a diagnostic and therapeutic challengeJoining the DoTS: new approach to classifying adverse drug reactionsTemporal and other factors that influence the time doctors take to prescribe using an electronic prescribing system.Clarification of terminology in drug safety.Over the counter medicines: proceed with cautionGuidelines for the diagnosis and management of individuals with neurofibromatosis 1Financial ties as part of informed consent to postmarketing research. Attitudes of American doctors and patientsMedication errors: problems and recommendations from a consensus meeting.A strategy for regulatory action when new adverse effects of a licensed product emerge.Harms from medicines: inevitable, in error or intentional.Where errors occur in the preparation and administration of intravenous medicines: a systematic review and Bayesian analysis.An analysis and comparison of commonly available United Kingdom prescribing resources.Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis.Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions: a systematic review.Susceptibilities.The medico-legal significance of pharmacokinetic interactions with ethanol.Systemic toxicity related to metal hip prostheses.The natural history of insulin secretion in type 1 diabetes.Adverse drug reactions in dermatology.The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions
P50
Q28165384-2464117B-5D25-433D-9EC3-5B4699E6B6F0Q28365909-9F46572A-A4E7-4980-8B33-5E888EA74B1CQ28369189-4E13CEE0-73A6-4539-8E21-DF9F9C5068CDQ28763974-62EEEF12-4B50-4B70-8569-BAA695847BA6Q30151502-B754A100-C4C4-4230-86D9-4340E008AA5CQ30396444-26934439-3328-4001-8709-105C5FA113B0Q33163620-0751C926-BC5A-4AD0-942D-7A526ABA4858Q33697056-56F40238-2386-4236-94F5-4BDA861A28B8Q33712336-1DD1524D-FF82-4D98-9E62-A75B892A6390Q33802866-673CBCB7-B57F-4994-90B2-3390390DF1D5Q34134230-E0441FBC-C0A7-4935-BE44-3CA829E59899Q34346084-28BA7CF4-EA09-40F6-9447-161B2FA66444Q34454377-B21C672D-3648-4378-B5F3-FA959374811AQ34532448-C9FD1BC5-960B-4397-A74F-D9F76672780FQ34543693-6B083F5D-8005-46A8-8360-E1793037BD3DQ34623044-16A826EF-CFE9-4CF2-99C3-EB8B55572365Q34647243-8A60506D-B2B4-47AE-B301-EC4B79E8DF51Q34756440-FDC1B814-DA0B-440D-B9E6-488D3611A280Q35003609-EB07E367-2F6C-49C1-B170-09DE16C96B4BQ35286031-58B253F0-98A1-49EC-A500-05B3B8646989Q35515999-5FA4559F-3789-4EBD-A5E3-77F3319016E7Q35590133-ED8884AD-687E-42B2-8F0F-A982DB99BEDCQ35611225-F629DDC4-B761-4914-A021-84073209D677Q36265926-FD7617C3-88D5-482D-B971-5773C1B29376Q36511944-A27CF55E-E4A5-4628-A5BF-96C3FA98B61FQ36653938-56079EA3-CF48-4484-845C-C0FAE7EDD29DQ36904068-8653A48E-9F32-445A-B271-43D34B6B1174Q37295589-76E9165E-4182-43CE-B7D6-B643BF9642F5Q37399071-3372FFB9-5B6B-44B9-90B0-036566E7BC0DQ37635191-112D6CC7-E962-4713-AE4B-F5A9805019C1Q37672030-175CC4F5-9B9A-4452-8221-E8BB09AC696BQ37787287-081C9A24-8EE7-4D0C-A33E-06BEDB6F28A5Q37823980-5193C0CE-323D-4F6A-BC09-F8A5ECAA642BQ37943436-811E4D24-C8FF-4930-8E85-4201927DD7C3Q38046749-0012D363-AB8D-4CD3-B639-B096D4A754B7Q38049985-FD2019ED-AF8B-4061-B167-CE39912A54AEQ38240816-4A9F08E9-AEDA-4281-B5E2-66B2F4E66CBAQ38253059-C7EAC670-00AA-44B2-AC9F-CDDC92FFBD9AQ38333021-ADF0A35B-D22D-482B-80CE-4DCF35C70726Q38539645-3413FFDA-BC8D-4E28-AAD5-1D6CC315C2F9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robin Ferner
@ast
Robin Ferner
@en
Robin Ferner
@es
Robin Ferner
@nl
Robin Ferner
@sl
type
label
Robin Ferner
@ast
Robin Ferner
@en
Robin Ferner
@es
Robin Ferner
@nl
Robin Ferner
@sl
prefLabel
Robin Ferner
@ast
Robin Ferner
@en
Robin Ferner
@es
Robin Ferner
@nl
Robin Ferner
@sl
P106
P31
P496
0000-0003-3769-1346